Lung Cancer
Conditions
Keywords
stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer, recurrent non-small cell lung cancer
Brief summary
RATIONALE: Vaccines made from a person's tumor cells may help the body build an effective immune response to kill non-small cell lung cancer cells. PURPOSE: This phase I trial is studying the effects of gp96-Ig vaccine therapy in treating patients with stage III, stage IV, or relapsed non-small cell lung cancer treated with first-line chemotherapy.
Detailed description
Overall Goals: \- to evaluate the safety and induction of anti-tumor immunity by administration of an immunogenic human tumor cell vaccine, and assess immune response in relation to clinical outcome. Primary Aim: \- to evaluate the safety of administering a heat shock protein gp96-Ig-secreting allogeneic tumor cell-vaccine (gp96-Ig vaccine) in patients with advanced NSCLC. Secondary Aims: * to study the immune response to vaccination, * to monitor clinical responses and * to recommend a dose-schedule combination for further testing in an initial Phase II trial of vaccine efficacy.
Interventions
BIOLOGICALAd100-gp96Ig-HLA A1
Dose Schedule 1 (DS-1): 4x10\^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10\^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10\^7 cells twice weekly, maximum 36 vaccines/patient
Sponsors
University of Miami
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed NSCLC (squamous, adeno-, large cell anaplastic, bronchoalveolar, and non-small cell carcinoma NOS): stage IIIB with malignant pleural effusion, stage IV, or recurrent disease. * At least one site of bi-dimensionally measurable disease. * Metastasis if present and treated must be stable by CT scan or MRI for at least 8 weeks. * Patient must have received and failed at least one line of chemotherapy. * Age \>= 18 years. * ECOG performance status 0-2. * Life expectancy \>= 3 months. * Laboratory parameters: * Hemoglobin levels \>= 10.0 (transfusions allowed if necessary). * ANC \>= 1,500. * Platelets \>= 100k. * Creatinine clearance \>= 50 ml/min. * Total and direct bilirubin: \< 2.5 X upper institution limit for normal. * Liver function tests: AST, ALT, and AlkP \< 2.5 X upper institution limit for normal. * Signed informed consent. * Autopsy consent - although not a requirement for study entry, patients who consent to participate in study will be made aware of the critical importance of a post-mortem examination in the event of the patient's death after receiving therapy with this experimental vaccine. Therefore, pre-treatment written agreement to autopsy will be sought from the patient, or verbal agreement to autopsy will be sought in the presence of the next of kin or other family members.
Exclusion criteria
* Active or symptomatic cardiac disease such as congestive heart failure, angina pectoris or recent myocardial infarction. Patients with history of these conditions who are stable taking cardiac medications will also be excluded. * Pregnant or lactating women (negative test for pregnancy is required of women of childbearing potential). * Known HIV infection. * Uncontrolled or untreated brain or spinal cord metastases. * Active infection. * Concomitant steroid or other immunosuppressive therapy. * Other active malignancies present within the past three years, except for basal and/or squamous cell carcinoma(s) or in situ cervical cancer. * Alcohol or chemical abuse. * Meningeal carcinomatosis. * Chemotherapy, radiation therapy, or other anti-tumor therapy during the last four weeks. * Prior biologic response modifier therapy. * Refusal in fertile men or women to use effective birth control measures during and for six months after the completion of treatment on study. * Immune deficiency syndromes, including the following: rheumatoid arthritis, systemic lupus erythematosus, Sjogren's disease, sarcoidosis, vasculitis, polymyositis, glomerulonephritis. * Compromised lung function: * FeV1 \< 30% of the predicted value, or * DLCO \< 30% of the predicted value, or * PCO2 \> 45 mmHg. * Any patient enrolled on study whose respiratory symptoms have experienced marked deterioration not related to a known cause, such as pneumonia, congestive heart failure, or pulmonary embolism, will have a repeat PFT evaluation, and if the above parameter values for FeV1, DLCO, or PCO2 are seen, will be excluded from further treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | 6, 12, 18, 24, and 36 months post enrollment |
Secondary
| Measure | Time frame |
|---|---|
| Immunologic response: CD8, CD4 and NK response | Baseline, Day 1 Week1, Day 1 Week 13, Day 1 Week 19 |
Countries
United States
Outcome results
None listed